Description

Cardinal Health: The Explosive Specialty Growth Story Wall Street May Be Underestimating!

Cardinal Health, Inc. reported third-quarter fiscal 2026 results marked by broad-based growth across segments, reflecting the firm’s diversified healthcare services and distribution portfolio. Total company revenue increased by 11% to $61 billion, underpinned chiefly by strong performance in the Pharmaceutical and Specialty Solutions segment and other growth businesses. Gross profit rose 18% to $2.5 billion, spurred by acquisitions and segment execution. Operating earnings grew 18% to $956 million, while non-GAAP EPS reached $3.17, representing 35% growth year-over-year. The company maintained disciplined capital allocation, completing a $1 billion share repurchase program year-to-date. The Pharmaceutical and Specialty Solutions segment expanded revenue by 11% to $56.1 billion, driven primarily by existing customer growth with specialty products contributing over 20% revenue growth and GLP-1 products adding 6 percentage points despite moderation from prior quarters. Segment profit increased 18% to $784 million, bolstered by brand and specialty product contributions and consistent generics market dynamics.